Quantcast

Latest Orphan drugs Stories

2011-06-02 12:47:00

FRANKLIN LAKES, N.J. and PORTLAND, Ore., June 2, 2011 /PRNewswire/ -- Medco Health Solutions, Inc. (NYSE: MHS) and MolecularMD Corp. today announce the launch of a personalized medicine program for chronic myeloid leukemia (CML) patients. Through this program, Medco will offer patients diagnosed with CML a molecular test known as qRT-PCR (quantitative real-time polymerase chain reaction) BCR-ABL to monitor the disease. (Logo: http://photos.prnewswire.com/prnh/20100609/MEDCOLOGO ) The...

2011-06-01 00:24:00

EAST HANOVER, N.J., June 1, 2011 /PRNewswire/ -- Novartis Pharmaceuticals Corporation ("Novartis") will showcase data from 140 abstracts on its current oncology products and investigational agents at the 47th Annual Meeting of the American Society of Clinical Oncology (ASCO). These data underscore the company's commitment to developing treatments to improve the lives of patients with cancer. "Through our commitment to R&D and collaborations with the scientific and patient communities,...

2011-05-19 19:48:00

SOUTH SAN FRANCISCO, Calif., May 19, 2011 /PRNewswire/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced updated results from the Phase 2b 003-A1 study of single-agent carfilzomib, a next generation proteasome inhibitor, in patients with relapsed and refractory multiple myeloma. Carfilzomib achieved a clinical benefit rate (CBR) (minimal response or greater) in the study population of 37 percent with a duration of response (DOR) of 8.3 months. The primary endpoint, overall...

2011-05-18 17:00:00

WAYNE, N.J. and SOUTH SAN FRANCISCO, Calif., May 18, 2011 /PRNewswire/ -- Bayer HealthCare Pharmaceuticals, Inc. and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced results from a Phase 2b trial evaluating Nexavar® (sorafenib) tablets in patients with locally advanced or metastatic breast cancer previously treated with a bevacizumab-containing regimen, which showed that Nexavar was associated with statistically significant improvements in progression-free...

2011-05-18 09:00:00

WAYNE, N.J. and SOUTH SAN FRANCISCO, May 18, 2011 /PRNewswire/ -- Bayer HealthCare Pharmaceuticals, Inc. and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that data evaluating the use of Nexavar® (sorafenib) tablets will be presented in a scientific forum at the 2011 Annual Meeting of the American Society of Clinical Oncology (ASCO), June 3-7, in Chicago. "Bayer and Onyx remain committed to researching the potential utility of sorafenib, and the number of...

2011-05-18 07:31:00

SOUTH SAN FRANCISCO, Calif., May 18, 2011 /PRNewswire/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced the presentation of several studies evaluating carfilzomib, a selective, next-generation proteasome inhibitor, and ONX 0912, an oral proteasome inhibitor, in hematological cancers at the 47th American Society of Clinical Oncology (ASCO) Annual Meeting, June 3-7, 2011 in Chicago, IL. "The data that will be presented at ASCO continue to support carfilzomib's potential as a new...

2011-05-06 15:00:00

SOUTH SAN FRANCISCO, Calif., May 6, 2011 /PRNewswire/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that it will present at the Bank of America Merrill Lynch Health Care Conference on Thursday, May 12, 2011 at 1:30 p.m. Eastern Time (10:30 a.m. Pacific Time). Interested parties may access a live webcast of the presentation on our website at: http://www.onyx-pharm.com/investors/event-calendar It is recommended that listeners log on 15 minutes early in order to register...

2011-05-06 08:54:00

SILVER SPRING, Md., May 6, 2011 /PRNewswire-USNewswire/ -- On Thursday, the U.S. Food and Drug Administration approved Afinitor (everolimus) to treat patients with progressive neuroendocrine tumors located in the pancreas (PNET) that cannot be removed by surgery or that have spread to other parts of the body (metastatic). (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO) Neuroendocrine tumors found in the pancreas are slow-growing and rare. It is estimated that there are fewer...

2011-05-04 09:45:00

WESTMINSTER, Colo., May 4, 2011 /PRNewswire/ -- Plato BioPharma, Inc. (PBI) and Gilead Sciences, Inc. will be jointly presenting a thematic poster at the "Novel Therapeutics in Pulmonary Fibrosis" session at the 2011 American Thoracic Society (ATS) International Conference in Denver, Colorado on May 18, 2011. The poster entitled Differing Effects of Ambrisentan and Bosentan on Pulmonary Fibrosis and Lung Mechanics Following Bleomycin Instillation will be presented by John Liles, PhD of...

2011-04-28 07:00:00

SOUTH SAN FRANCISCO, Calif., April 28, 2011 /PRNewswire/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced the presentation of several studies evaluating carfilzomib, a selective, next-generation proteasome inhibitor, at the 13th International Myeloma Workshop (IMW), May 3-6, 2011, in Paris, France. "The data we are accumulating for carfilzomib continues to support its potential as an important new treatment option for patients with multiple myeloma. Data from several studies...


Word of the Day
humgruffin
  • A terrible or repulsive person.
Regarding the etymology of 'humgruffin,' the OED says (rather unhelpfully) that it's a 'made-up word.' We might guess that 'hum' comes from 'humbug' or possibly 'hum' meaning 'a disagreeable smell,' while 'gruffin' could be a combination of 'gruff' and 'griffin.'